SAPHO syndrome is a rare condition that brings together bone inflammation, joint problems, and skin changes in ways that can deeply affect a person’s daily life. The name stands for Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis, reflecting the variety of symptoms patients may experience. While the cause remains unknown, doctors and researchers are working to find better ways to control symptoms, reduce pain and inflammation, and improve the quality of life for those living with this condition.

What Can Be Done to Manage SAPHO Syndrome

The main goals of treatment in SAPHO syndrome focus on relieving pain, reducing inflammation in the bones and joints, and addressing skin problems. Because the syndrome affects different parts of the body in different ways, each person may need a unique combination of treatments. Some patients struggle primarily with severe bone pain and stiffness, while others are more troubled by skin symptoms like pustules or acne. The approach to treatment must consider the severity of symptoms, which parts of the body are involved, and how the condition affects a person’s ability to work, move, and participate in daily activities.^[1][2]

There is currently no cure for SAPHO syndrome, so treatment aims to control symptoms rather than eliminate the disease entirely. Many patients experience periods when symptoms worsen, called flare-ups, followed by times when symptoms improve or disappear. Managing the condition often requires patience and ongoing communication with healthcare providers, as it may take time to find the right combination of treatments that work for each individual. The condition can be chronic, meaning it lasts for years, but many patients eventually experience improvement or even complete resolution of symptoms over time.^[4][12]

Because SAPHO syndrome can involve both rheumatologic and dermatologic manifestations, care often involves a team approach. Rheumatologists typically manage joint and bone symptoms, while dermatologists address skin problems. This collaboration helps ensure that all aspects of the condition are treated effectively. Standard treatments have been used for years with varying degrees of success, while newer approaches tested in clinical research settings offer hope for better outcomes in the future.^[8][15]

Standard Treatment Options Currently in Use

Nonsteroidal anti-inflammatory drugs, commonly called NSAIDs, are often the first medications prescribed for SAPHO syndrome. These drugs help reduce pain and inflammation in the joints and bones. Examples include ibuprofen, which many people recognize, and lornoxicam, which has been used in some reported cases. NSAIDs work by blocking certain chemicals in the body that cause inflammation and pain. They are generally considered safe for short-term use, but long-term use may cause stomach problems, kidney issues, or increase the risk of heart problems. Patients are usually advised to take the lowest effective dose for the shortest time necessary.^[5][7]

For patients whose symptoms do not respond adequately to NSAIDs alone, doctors may prescribe disease-modifying antirheumatic drugs, or DMARDs. Sulfasalazine is one such medication frequently used in SAPHO syndrome. It was originally developed to treat inflammatory bowel disease but has proven helpful for joint inflammation in various rheumatic conditions. Methotrexate is another DMARD sometimes prescribed, particularly when joint involvement is significant. These medications work more slowly than NSAIDs, often taking weeks or months to show their full effect, but they can help reduce the underlying inflammation rather than just masking symptoms.^[4][12]

Corticosteroids are powerful anti-inflammatory medications that can be used in different ways for SAPHO syndrome. Some patients receive systemic corticosteroids, meaning pills or injections that affect the whole body, while others may benefit from local steroid injections directly into painful joints or areas of bone inflammation. Corticosteroids work quickly to reduce inflammation and can provide significant relief during severe flare-ups. However, long-term use carries risks including weight gain, bone thinning, increased blood sugar, and increased susceptibility to infections. Doctors typically try to use the lowest dose possible and gradually reduce the dose over time.^[4][12]

For skin symptoms, particularly severe acne or palmoplantar pustulosis, dermatologists may prescribe oral retinoids, which are derivatives of vitamin A. Isotretinoin is used for severe acne, while acitretin may be chosen for pustulosis affecting the palms and soles. These medications work by reducing oil production in the skin and decreasing inflammation. They require careful monitoring because they can cause dry skin, increased sensitivity to sunlight, changes in blood lipid levels, and, most importantly, severe birth defects if taken during pregnancy. Women of childbearing age must use effective contraception while taking these medications and for some time afterward.^[4][12]

Bisphosphonates have emerged as an important treatment option, particularly for bone symptoms. These medications, which include pamidronate and other similar drugs, were originally developed to treat osteoporosis and have been found helpful for the bone inflammation and pain characteristic of SAPHO syndrome. Bisphosphonates work by slowing down the activity of cells that break down bone, thereby reducing bone turnover and inflammation. Many case reports and small studies have suggested bisphosphonates as a first-line option for bone symptoms, with some patients experiencing significant improvement in pain and stiffness. The medications can be given as intravenous infusions or oral tablets, depending on the specific drug chosen.^[3][4]

Other medications that may be tried include colchicine, a drug traditionally used for gout that has anti-inflammatory properties; calcitonin, a hormone involved in bone metabolism; and ciclosporin, an immunosuppressive medication. The choice among these various options depends on which symptoms are most troublesome, how severe they are, previous treatment responses, and potential side effects. Treatment duration varies considerably, with some medications used for weeks or months during flare-ups, while others may be continued for years if they prove effective and well-tolerated.^[4][12]

Promising Treatments Being Tested in Clinical Research

Researchers have been exploring newer medications called biologics for SAPHO syndrome. These are sophisticated drugs developed using biotechnology that target specific parts of the immune system. Unlike traditional medications that work more broadly, biologics are designed to block particular inflammatory molecules or pathways involved in disease. Because SAPHO syndrome is thought to involve abnormal immune system activation, these targeted approaches hold considerable promise.^[8][15]

Tumor necrosis factor inhibitors, or TNF blockers, are one class of biologics that has been tried in SAPHO syndrome. TNF is a protein in the body that promotes inflammation, and blocking it can reduce inflammatory symptoms. Medications in this category include infliximab, etanercept, and adalimumab. These drugs have been tested in various clinical studies and case reports, with mixed results. Some patients have experienced significant improvement in bone and joint symptoms, while others have shown little response. Interestingly, some reports suggest these medications may be more effective for joint and bone symptoms than for skin manifestations, though this pattern is not universal. TNF inhibitors are typically given as injections under the skin or as intravenous infusions, and they work by binding to TNF and preventing it from triggering inflammation.^[3][4][8]

A newer category of biological treatments targets interleukin-17, or IL-17, another inflammatory protein that appears to play a role in SAPHO syndrome. IL-17 inhibitors have shown promise in treating conditions similar to SAPHO, particularly psoriatic arthritis and ankylosing spondylitis. Early experiences with these medications in SAPHO patients suggest they may be effective for both bone and skin symptoms. This dual benefit is particularly exciting because many other treatments tend to work better for either bones or skin, but not both. The mechanism involves blocking IL-17 from binding to its receptors on cells, thereby interrupting the inflammatory cascade that contributes to symptoms.^[8][15]

Another interleukin being targeted is IL-1, and medications that block this inflammatory protein are called IL-1 inhibitors. Given that SAPHO syndrome is classified as an autoinflammatory disease, and IL-1 plays a central role in autoinflammatory processes, these medications represent a logical treatment approach. Clinical experiences with IL-1 inhibitors in SAPHO patients have been reported, with some showing improvement in osteoarticular symptoms. These medications work by preventing IL-1 from activating inflammatory pathways in the body.^[8][15]

A particularly interesting recent development involves JAK inhibitors, which are small molecule drugs rather than large biologic antibodies. JAK stands for Janus kinase, a family of enzymes involved in transmitting signals from various inflammatory proteins into cells. By blocking these enzymes, JAK inhibitors can interrupt multiple inflammatory pathways at once. Baricitinib is one JAK inhibitor that has been reported in at least one detailed case of SAPHO syndrome. In this case, a patient who had not responded adequately to multiple other treatments, including biologics, experienced remarkable improvement in both skin and bone symptoms within two weeks of starting baricitinib. The patient remained well without disease recurrence during follow-up. This represents a promising option, though more studies are needed to confirm these findings in larger groups of patients.^[11][8]

An oral medication called apremilast has also been explored for SAPHO syndrome. This drug works by inhibiting an enzyme called phosphodiesterase 4, which plays a role in inflammation. Apremilast is taken as a pill, which some patients find more convenient than injectable biologics. It has shown promise in treating both osteoarticular and skin symptoms in SAPHO patients, though research is still in relatively early stages. The mechanism involves reducing the production of various inflammatory molecules while increasing anti-inflammatory signals in the body.^[8][15]

Interestingly, a traditional Chinese medicine preparation called Tripterygium wilfordii Hook F has been evaluated in research settings for SAPHO syndrome. This plant extract has been used in traditional medicine for inflammatory conditions and has been found to have immunomodulatory effects, meaning it can alter how the immune system functions. Some studies suggest it may be effective in reducing symptoms, particularly bone and joint manifestations. However, it requires careful monitoring due to potential side effects, and more research is needed to establish optimal dosing and safety profiles.^[8]

Most of these newer treatments are still being evaluated through clinical trials or are documented primarily through case reports and small patient series. Clinical trials for rare diseases like SAPHO syndrome face challenges because there are relatively few patients, making it difficult to gather large numbers of participants. Trials typically progress through phases: Phase I focuses primarily on safety in a small number of people; Phase II evaluates whether the treatment shows signs of effectiveness and continues safety monitoring in a larger group; Phase III compares the new treatment to standard treatments or placebo in even larger groups to confirm effectiveness and monitor for side effects that may not have appeared in earlier phases.^[16][15]

Because SAPHO syndrome affects different systems and involves complex inflammatory pathways, researchers increasingly recognize that different treatments may work better for different symptoms. For example, IL-17 inhibitors and JAK inhibitors appear promising for both bone and skin symptoms, while TNF inhibitors may be more effective for osteoarticular manifestations. This growing understanding is leading to more personalized treatment recommendations based on which symptoms predominate in each patient. Future research will likely focus on identifying which patients will respond best to which treatments, a concept called precision medicine.^[8][15]

Most common treatment methods

• Nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Include medications like ibuprofen and lornoxicam that reduce pain and inflammation in joints and bones
  • Generally used as first-line treatment for symptom relief
  • Work by blocking inflammatory chemicals in the body
• Disease-modifying antirheumatic drugs (DMARDs)
  • Include sulfasalazine and methotrexate for reducing underlying inflammation
  • Take weeks to months to show full effect
  • Help control joint involvement when NSAIDs alone are insufficient
• Bisphosphonates
  • Medications like pamidronate that target bone inflammation and pain
  • Suggested as first-line therapy for bone symptoms in many cases
  • Work by reducing bone turnover and inflammation
• Corticosteroids
  • Powerful anti-inflammatory medications given systemically or as local injections
  • Provide rapid relief during severe flare-ups
  • Long-term use requires careful monitoring due to potential side effects
• Oral retinoids
  • Vitamin A derivatives including isotretinoin for acne and acitretin for pustulosis
  • Specifically target skin manifestations of SAPHO syndrome
  • Require strict pregnancy prevention measures due to risk of birth defects
• Antibiotics
  • Particularly clindamycin, used based on findings of Propionibacterium acnes in bone biopsies
  • Treatment courses typically last three to eight months
  • Some patients experience prolonged symptom-free periods after treatment
• Biologic therapies
  • TNF inhibitors like infliximab, etanercept, and adalimumab that block tumor necrosis factor
  • IL-17 inhibitors that show promise for both bone and skin symptoms
  • IL-1 inhibitors targeting autoinflammatory pathways
  • Given as injections or intravenous infusions
• JAK inhibitors
  • Small molecule drugs like baricitinib that block Janus kinase enzymes
  • Can interrupt multiple inflammatory pathways simultaneously
  • Case reports show rapid improvement in both skin and bone symptoms
  • Taken orally rather than by injection
• Other immunomodulatory treatments
  • Apremilast, a phosphodiesterase 4 inhibitor taken orally
  • Tripterygium wilfordii Hook F, a traditional Chinese medicine with anti-inflammatory effects
  • Various other medications including colchicine, calcitonin, and ciclosporin for specific situations